European Medicines Agency (EMA) starts rolling review of REGN-COV2 antibody combination (casirivimab / imdevimab) for treatment and prevention of COVID-19

The decision to start rolling review is based on preliminary results from a study indicating beneficial effect of the combination in reducing viral load in non-hospitalised patients with COVID-19. The CHMP will evaluate all data as they become available.

Source:

European Medicines Agency